

For Adult Patients Taking Tasigna® (nilotinib) capsules¹

 **Danziten**[™]
(nilotinib) tablets 71mg, 95mg

**Danziten[™] is the Only Nilotinib
Without Mealtime Restrictions.**

Eat Whenever You Want!^{2,a,*}



Learn more

a. Patients should not consume grapefruit products and other foods that are known to inhibit CYP3A4 at any time during Danziten[™] treatment.

1. Tasigna (prescribing information); East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2024.

2. DANZITEN [prescribing information], Woburn, MA: Azurity Pharmaceuticals, Inc., 2024.

* Patients on Tasigna® should avoid food 2 hours before and 1 hour after taking dose.

© 2025 Azurity Pharmaceuticals, Inc. All Rights Reserved. Danziten[™] is a trademark of Azurity Pharmaceuticals, Inc. All trademarks referred to are the property of their respective owners. Tasigna® is a registered trademark of Novartis Pharmaceutical Corporation PP-DAN-US-0177



FPO

WARNING: QT PROLONGATION and SUDDEN DEATHS
See Full Prescribing Information for complete Boxed Warning.

- Nilotinib prolongs the QT interval. Prior to DANZITEN administration and periodically, monitor for hypokalemia or hypomagnesemia and correct deficiencies. (5.3) Obtain ECGs to monitor the QTc at baseline, seven days after initiation, and periodically thereafter; and following any dose adjustments. (5.3, 5.4, 5.8, 5.12)
- Sudden deaths have been reported in patients receiving nilotinib. (5.4) Do not administer DANZITEN to patients with hypokalemia, hypomagnesemia, or long QT syndrome. (4, 5.3)
- Avoid use of concomitant drugs known to prolong the QT interval and strong CYP3A4 inhibitors. (7.1, 7.2)